Talampicillin (hydrochloride) is a ampicillin derivative. Talampicillin (hydrochloride) is a thiazolide carboxylic ester of ampicillin. Talampicillin (hydrochloride) can be studied in research on urinary infection.

Tafuramycin A, a Duocarmycin derivative, is a potent anticancer and parasite attenuating agent. Tafuramycin A can be used for triple-negative breast cancer (TNBC) and malaria infection research.

TACE-IN-1 is an orally active hydantoin-based tumor necrosis factor-α converting enzyme (TACE) inhibitor. TACE-IN-1 inhibits the production of TNF-α in human whole blood. TACE-IN-1 can be prepared as a stable neutral form. TACE-IN-1 can be used in anti-inflammatory research.

T3SS-IN-6 is a thiazolidin-2-cyanamide derivative and type III secretion system (T3SS) inhibitor targeting Xanthomonas oryzae pv. oryzae (Xoo). T3SS-IN-6 exhibits no effect on Xoo growth. T3SS-IN-6 shows no measurable acute toxicity to silkworms and earthworms.

T133 is an orally active ATP-competitive mTOR inhibitor with an IC50 of 0.34 nM and a Ki of 0.17 nM. T133 suppresses phosphorylation of AKT, S6K1, and 4EBP1. T133 inhibits cancer cell proliferation and migration, induces apoptosis, cell cycle arrest, and autophagy. T133 exhibits dose-dependent antitumor efficacy in xenograft mouse models. T133 can be used for the research of cancer, such as gastric cancer and lung cancer.

SYAF080 is a human A₂B adenosine receptor (hA₂B AdoR) antagonist with a Ki of 23.6 nM and a KB of 25.2 nM. SYAF080no relevant inhibition of human CYP450 cytochromes. SYAF080 can be used for the research of inflammation, metabolic and cardiovascular disease.

SY-589 is an orally active DNA polymerase Polθ helicase domain inhibitor (IC50=2.29 nM) and DNA damage inducer. SY-589 inhibits the ATPase activity of the Polθ helicase domain and blocks the Polθ-mediated microhomology-mediated end joining (MMEJ) DNA repair pathway (IC50=0.85 nM). SY-589 also induces the accumulation of DNA double-strand breaks by increasing γ-H2AX levels. SY-589 exerts antiproliferative effects on BRCA2-deficient cells and is used in the research of HR-deficient tumors.

SUVN-507 is a 5-HT6 receptor antagonist. SUVN-507 can reverse cognitive impairments and enhance excitatory neural transmission while weakening inhibitory neural transmission. SUVN-507 can be used for the research of neurological disease, such as Alzheimer's disease.

Sumacetamol (SUR 2647) is the N-acetyl-DL-methionine ester of Paracetamol. Sumacetamol is orally active. Sumacetamol enhances the hepatic GSH synthesizing capacity in Bom:NMRI mice after experimental overdosage and offers protection of hepatic cell integrity, when combined with Paracetamol .

Sulfiflumin (compound I) is a thiazolidine acaricide. Sulfiflumin can be used as a plant protection agent.

Sucrose dilaurate acts as an emulsifier, dispersant and stabilizer. Sucrose dilaurate reduces the release of HMGB1 from UVB-irradiated keratinocytes. Sucrose dilaurate inhibits melanogenesis and decreases bilirubin levels. Sucrose dilaurate induces autophagy in human epidermal keratinocytes, thereby reducing carboxymethyl lysine (CML) levels. Sucrose dilaurate reduces the secretion of insulin-like growth factor-binding protein 3 (IGFBP3) and nerve growth factor (NGF) by senescent keratinocytes. Sucrose dilaurate is investigated as an emulsifier, dispersant or stabilizer in the cosmetics, food and pharmaceutical industries.

SU212 is a podophyllotoxin-derived ENO1 inhibitor and AMPK activator. SU212 can selectively induce oxidative phosphorylation, reduce glycolysis activity and glucose uptake in tumor cells, and directly bind to ENO1 without affecting these pathways in normal cells. SU212 induces apoptosis and promotes ENO1 degradation via proteasomal and autophagic pathways without inhibiting the catalytic activity. SU212 leads to mitotic arrest and apoptosis in TNBC (triple-negative breast cancer) cells by activating AMPK, demonstrating potent anti-tumor activity in vitro. SU212 inhibits tumor growth and metastasis in syngeneic, xenograft, and diabetic mouse models, exhibiting an excellent safety profile. SU212 can be used in research on t TNBC, diabetes, and fatty liver disease.

STING agonist-51 (Example 3) is a bis-benzimidazole STING agonist.STING agonist-51 can be used for the research of cancer.

STING agonist-50 is an orally active STING agonist with an IC50 of 3.457 μM. STING agonist-50 activates the STING signaling pathway and promotes the phosphorylation of downstream TBK1 and IRF3. STING agonist-50 induces the expression of IFN-β, CXCL10 and IL-6. STING agonist-50 inhibits tumor growth in syngeneic mouse models. STING agonist-50 can be used for the research of colorectal cancer.

STIM1-TFR1-IN-1 is a stromal interaction molecule 1 (STIM1)-transferrin receptor 1 (TFR1) protein complex inhibitor with a Kd of 2.18 μM for STIM1-CD protein. STIM1-TFR1-IN-1 blocks STIM1-TFR1 interaction and reduce TFR1-mediated iron uptake activity. STIM1-TFR1-IN-1 inhibits ferroptosis, lipid peroxidation and ROS production, enhances glutathione peroxidase 4 (GPX4) activity and glutathione/oxidized glutathione ratio, and rescues ferroptosis-associated mitochondrial morphological changes. STIM1-TFR1-IN-1 exhibits neuroprotectiveeffects and reduces brain injury. STIM1-TFR1-IN-1 can be used for the research of intracerebral hemorrhage.

Steroid sulfatase-IN-11 is a steroid sulfatase inhibitor, which functionally inhibits steroid sulfatase activity, reducing the enzyme's ability to hydrolyze steroid sulfates. Steroid sulfatase-IN-11 can be used for the research of hormone-dependent cancers.

STAT6-IN-11 (example 3) is a STAT6 inhibitor with an EC50 of 6 nM. STAT6-IN-11 inhibits CCL17 secretion in peripheral human whole blood, stimulated through the IL-13-IL- 13 receptor/IL-4 receptor pathway, with an IC50 of 83 nM. STAT6-IN-11 can be used for the study of dermatological condition or a respiratory condition.

STAT6-IN-10 (example 10) is a signal transducer and activator of transcription 6 (STAT6) inhibitor with an EC50 of 0.002 μM. STAT6-IN-10 inhibits CCL17 secretion in peripheral human whole blood with an IC50 of 0.095 μM. STAT6-IN-10 can be used for dermatological condition and respiratory condition research.

STAT6 degrader-1 (Compound 21) is a bifunctional molecular glue degrader of STAT6 that recruits E3 ubiquitin ligase. STAT6 degrader-1 induces proteasomal degradation of STAT6. STAT6 degrader-1 is applicable to the research of cancer, inflammatory diseases and colorectal cancer.

STAT3-IN-53 (Compound L20) is a STAT3 inhibitor with a Kd value of 6.16 μM. STAT3-IN-53 binds directly to the SH2 domain of STAT3, inhibits phosphorylation at the Y705 site without affecting the total STAT3 protein level, and suppresses the IL-6/JAK/STAT3 pathway. STAT3-IN-53 downregulates the transcription and expression of cyclin-D1 and c-Myc. STAT3-IN-53 induces cell cycle arrest and promotes Apoptosis. STAT3-IN-53 exhibits anticancer activity against colorectal cancer.

STAT3-IN-33 (compound 7f) is a potent STAT3 inhibitor with anti-cancer activity. STAT3-IN-33 exhibits antiproliferative activity in HCT116, MCF-7, and MDA-MB-231 cells, with IC50s of 6.44, 3.29, and 4.86 μM, respectively. STAT3-IN-33 can be used for breast and colon cancer research.

ST1072 is a dual inhibitor of CerS4 and CerS6. ST1072 significantly reduces the ability of murine T cells to proliferate and produce IFN-γ. ST1072 can be used for hematologic malignancies research.

WAY-230563 (ST045945) is a serine/threonine kinase inhibitor that can block CHK1/CHK2-mediated cell cycle checkpoints. WAY-230563 can induce G2/M phase arrest and DNA damage in tumor cells.

SSTR3 Agonist-1 (Compound EX 38) is an orally active SSTR3 agonist, with an EC50 of 0.14 nM. SSTR3 Agonist-1 reduces the kidney cystic index. SSTR3 Agonist-1 can be used in the research of autosomal dominant polycystic kidney disease.

SR-THAP is a γ-aminobutyric acid transporter 3 (GAT3) inhibitor with an IC50 of 4.9 μM, and exhibits 42-fold and 23-fold selectivity over GAT1 and GlyT1, respectively. SR-THAP inhibits GABA uptake in mammalian cells. SR-THAP is applicable to the research of epilepsy, Alzheimer's disease and ischemic stroke.

SR-5037 is an orally active CDK12 (IC50 = 31 nM)/CDK13 inhibitor and CycK (DC50 = 30 nM;Dmax > 98%) molecular glue degrader. SR-5037 inhibits the enzymatic activity of CDK12/CycK and CDK13/CycK complexes. SR-5037 promotes the recruitment of DDB1 to the CDK12/CycK complex, thereby triggering proteasome-mediated CycK degradation. SR-5037 degrades active CycK in mouse models of triple-negative breast cancer. SR-5037 can be used in the research of cancers such as triple-negative breast cancer.

SP187 hydrochloride (MON-DNJ hydrochloride; UV4 hydrochloride) is an orally active, host-targeting iminosaccharide against filovirus infection. SP187 hydrochloride inhibits endoplasmic reticulum glucosidase. SP187 hydrochloride exhibits antiviral and Dengue Virus activity in vivo. SP187 hydrochloride can be used in antiviral and dengue research.

SOS1-IN-25 is an SOS1 inhibitor. SOS1-IN-25 exhibits inhibitory activity against KRASG12C/SOS1 complex formation (IC50 = 11.11 nM). SOS1-IN-25 leads to a dose-dependent decrease in pERK levels. SOS1-IN-25 can be used for the study of leukemia.

Sodium Channel-IN-8 (Example 96) is a voltage-gated sodium channel (NaV1.7) inhibitor.Sodium Channel-IN-8 can be used for the research of pain.

Sodium Channel-IN-7 (Example 59) is a NaV1.7 voltage-gated sodium channel inhibitor.Sodium Channel-IN-7 binds to the VSD4 binding pocket of NaV1.7, with reduced interaction with Try1537.Sodium Channel-IN-7 can be used for the research of pain.